Author:
Uwingabiye Jean,Zahid Hafid,El Amrani Mohamed,Labrini Fayçal,Elkhazraji Abdelhak,El Kabbaj Driss,Benyahia Mohammed,Yahyaoui Anass,Hadef Rachid,Messaoudi Nezha
Publisher
Springer Science and Business Media LLC
Subject
Hematology,Molecular Biology
Reference25 articles.
1. Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost. 2011;37(3):209–19.
2. Coppola A, Tufano A, Di Capua M, Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost. 2011;37(8):929–45.
3. Reece EA, Clyne LP, Romero R, Hobbins JC. Spontaneous factor XI inhibitors seven additional cases and review of the literature. Arch Intern Med. 1984;144(3):525–9.
4. Billon S, Blouch MT, Escoffre-Barbe M, Niger CL, Abgrall JF, Roux AM. Les inhibiteurs anti-facteur XI : caractéristiques cliniques et biologiques. Ann Biol Clin (Paris). 2001;59(2):183–6.
5. Teng HW, Chen PM, Yang YH, Gau JP. The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma. Jpn J Clin Oncol. 2007;37(8):609–14.